Format

Send to

Choose Destination
Dis Markers. 2016;2016:7157039. doi: 10.1155/2016/7157039. Epub 2016 Jul 27.

Expressions of Endocan in Patients with Meningiomas and Gliomas.

Author information

1
Department of Biochemistry, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey.
2
Department of Neurosurgery, Samatya Training and Research Hospital, Istanbul, Turkey.
3
Department of Neurosurgery, Cerrahpasa Medical Faculty, Istanbul University, Fatih, 34098 Istanbul, Turkey.
4
Department of Forensic Medicine, Uludag University, Bursa, Turkey.

Abstract

OBJECTIVE:

Endocan has been shown to be a marker for several cancers and may show degree of malignancy. The aim of this study is to assess tissue levels of endocan in common brain tumors, namely, meningiomas, low-grade gliomas (LGGs), and high-grade gliomas (HGGs).

PATIENTS AND METHODS:

Endocan was assayed by commercially available enzyme linked immunosorbent assay (ELISA) kits in a total of 50 brain tumors (20 meningiomas, 19 LGGs, and 20 HGGs) and 15 controls. The results were compared to control brain tissues.

RESULTS:

Each tumor group showed significant higher levels of endocan compared to controls (p < 0.05). In addition, endocan levels showed steady increase from the least (meningiomas) to the most (HGGs) malignant tumors and positive correlation was noted between the degree of malignancy and endocan level (p = 0.0001).

CONCLUSION:

Endocan, a vital molecule for angiogenesis, is expressed in common brain tumors and results suggest that endocan could be a marker for malignancy.

PMID:
27528791
PMCID:
PMC4978841
DOI:
10.1155/2016/7157039
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Hindawi Limited Icon for PubMed Central
Loading ...
Support Center